Publicação
Deciphering the interplay of molecular alterations underpinning renal cell carcinoma by label-free mass spectrometry and clinical proteomics: A systems medicine approach for precision diagnosis
| datacite.subject.fos | Engenharia e Tecnologia::Engenharia Química | pt_PT |
| dc.contributor.advisor | Santos, Hugo | |
| dc.contributor.advisor | LaFramboise, William | |
| dc.contributor.advisor | Lodeiro Espiño, Carlos | |
| dc.contributor.author | Penedo, Susana Patrícia Guerreiro Jorge | |
| dc.date.accessioned | 2021-04-09T09:30:18Z | |
| dc.date.available | 2021-04-09T09:30:18Z | |
| dc.date.issued | 2021-02 | |
| dc.date.submitted | 2020 | |
| dc.description.abstract | Renal neoplasia is the 14th most common tumor type diagnosed worldwide. With a vast heterogeneity, renal neoplasia encompasses different subtypes. 90% of the neoplasms arise from the epithelial layer of the nephron and vary from benign renal masses (renal oncocytoma, RO) to more indolent or aggressive cancers (renal cell carcinomas, RCC). As RCC subtypes, clear cell (ccRCC) subtype is the most predominant subtype, followed by papillary (pRCC) and chromophobe (chRCC). Despite the different outcomes, some overlapped histological and morphological features difficult their differentiation and diagnosis. Therefore, new approaches for a clear and accurate diagnosis are still needed. To achieve this goal, renal tissue biopsies diagnosed with ccRCC (n = 7), pRCC (n = 5), chRCC (n = 5), RO (n = 5) and normal adjacent tissue (NAT, n= 5) were enrolled in this study. As a very resourceful tool for proteome analysis and biomarker discovery, mass spectrometry (MS)-based methods were used to interrogate the proteome of each tumor in order to undisclosed differences trough which to develop faster and accurate diagnostics. The results achieved with this doctoral thesis include i) the accomplishment of an effective ultrasonic workflow to recover the proteome of optimal cutting temperature (OCT)-embedded tissues, ii) a novel analytical approach based on MALDI-MS profiling to distinguish chRCC from RO, iii) a 109-protein panel to discriminate between chRCC and RO and NAT, iv) a top 24-protein panel to diagnose ccRCC, pRCC, chRCC and RO based on absolute concentration values, v) the translation and validation of three promising biomarkers by immunohistochemical analysis, and vi) an approach for phosphopeptide enrichment. This work brings new insights into the different mechanisms underlying formation of these tumors as well as it provides valuable information to improve clinical diagnosis by opening new avenues for immunohistochemistry and mass spectrometry-based approaches. | pt_PT |
| dc.identifier.uri | http://hdl.handle.net/10362/115264 | |
| dc.language.iso | eng | pt_PT |
| dc.subject | Renal tumors | pt_PT |
| dc.subject | Differential diagnosis | pt_PT |
| dc.subject | Mass spectrometry | pt_PT |
| dc.subject | Proteome analysis | pt_PT |
| dc.title | Deciphering the interplay of molecular alterations underpinning renal cell carcinoma by label-free mass spectrometry and clinical proteomics: A systems medicine approach for precision diagnosis | pt_PT |
| dc.type | doctoral thesis | |
| dspace.entity.type | Publication | |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | doctoralThesis | pt_PT |
| thesis.degree.name | Doutor em Química | pt_PT |
Ficheiros
Principais
1 - 1 de 1